文献速递食管胃疾病与幽门螺杆菌

TOP-GERD试验:替戈拉生与泮托拉唑治疗非亚洲人群糜烂性食管炎的疗效比较

The TOP-GERD Trial: Comparative Efficacy of Tegoprazan Versus Pantoprazole in the Treatment of Erosive Oesophagitis in a Non-Asian Population.
PubMed 文献 · Aliment Pharmacol Ther · 2026-10-03

这项在墨西哥成人中开展的多中心随机双盲对照试验,比较替戈拉生50mg每日一次与泮托拉唑40mg每日一次治疗洛杉矶分级B-D级糜烂性食管炎4周的疗效。意向治疗人群中内镜愈合率分别为88.9%和79.4%(p=0.33),差异无统计学意义;替戈拉生症状改善更快,在严重食管炎亚组中愈合率更高。

要点

  • 4周内镜愈合率替戈拉生88.9% vs 泮托拉唑79.4%,差异无统计学意义
  • 替戈拉生第一周症状改善≥50%者占84.4%,显著高于泮托拉唑的31.3%
  • 洛杉矶C/D级亚组中替戈拉生愈合率100% vs 泮托拉唑68.8%(p=0.04)

核心结论

  • 意向治疗人群4周内镜愈合率替戈拉生与泮托拉唑差异无统计学意义(88.9% vs 79.4%,p=0.33)。
  • 替戈拉生症状改善更快,严重食管炎亚组愈合率更高,值得进一步研究。

研究设计与样本

  • 多中心、随机、双盲、活性对照试验,纳入墨西哥成人洛杉矶分级B-D级糜烂性食管炎患者。

主要发现

  • 意向治疗人群内镜愈合率替戈拉生88.9%、泮托拉唑79.4%(p=0.33)。
  • 符合方案人群愈合率替戈拉生100%、泮托拉唑84.4%(p=0.053)。
  • 洛杉矶C/D级亚组符合方案愈合率替戈拉生100%、泮托拉唑68.8%(p=0.04)。
  • 第一周症状改善≥50%者替戈拉生84.4%、泮托拉唑31.3%(p<0.001),替戈拉生自第1天起完全症状缓解更常见。
  • 两组症状严重程度和健康相关生活质量均改善,不良事件少见、轻微且与治疗无关。

关键数值与推荐

  • 主要终点为第4周内镜愈合优效性,意向治疗人群差异9.5%(p=0.33)。
  • 洛杉矶C/D级亚组符合方案愈合率差异有统计学意义(p=0.04)。

临床怎么用

  • 替戈拉生50mg每日一次可作为糜烂性食管炎尤其是严重食管炎患者抑酸治疗的候选方案。
  • 替戈拉生起效更快,可能有助于早期症状控制。

局限性

  • 研究仅纳入墨西哥成人,结果外推至其他非亚洲人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Potassium-competitive acid blockers provide rapid and sustained acid suppression, but tegoprazan has not been studied in non-Asian populations. AIM: To compare the efficacy and safety of tegoprazan 50 mg once daily with pantoprazole 40 mg once daily for healing erosive oesophagitis and improving reflux symptoms. METHODS: In this multicentre, randomized, double-blind, active-controlled trial, Mexican adults with Los Angeles grade B-D erosive oesophagitis received tegoprazan or pantoprazole for 4 weeks. The primary outcome was superior endoscopic healing at week 4. Secondary outcomes included early symptom response, complete symptom resolution, changes in symptom severity, health-related quality of life, and adverse events. RESULTS: Seventy participants were randomized and 64 completed treatments. In the intention-to-treat population, endoscopic healing occurred in 88.9% receiving tegoprazan and 79.4% receiving pantoprazole (p = 0.33). In the per-protocol population, healing occurred in 100% and 84.4%, respectively (p = 0.053). Among participants with Los Angeles grade C or D oesophagitis, per-protocol healing rates were 100% with tegoprazan and 68.8% with pantoprazole (p = 0.04). During the first treatment week, at least 50% symptom improvement occurred in 84.4% and 31.3%, respectively (p < 0.001), and complete symptom resolution was more frequent with tegoprazan from day 1. Symptom severity and health-related quality of life improved in both groups. Adverse events were infrequent, mild, and unrelated to treatment. CONCLUSIONS: There was a nonsignificant 9.5% difference in the primary intention-to-treat 4-week healing endpoint between tegoprazan and pantoprazole. Tegoprazan provided faster symptom improvement, while the per-protocol findings and the higher healing rate observed in the exploratory severe oesophagitis subgroup were encouraging and warrant further investigation. (ClinicalTrials.gov Identifier: NCT06991348).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Remes-Troche JM, Valdovinos-García LR, Gyawali CP, et al. The TOP-GERD Trial: Comparative Efficacy of Tegoprazan Versus Pantoprazole in the Treatment of Erosive Oesophagitis in a Non-Asian Population. Aliment Pharmacol Ther. 2026. PMID: 42829447. doi:10.1111/apt.71032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。